Holen Sie sich die Stockscreener-App
0.9875
0.78%
0.0076
Schlusskurs vom Vortag:
$0.9799
Offen:
$0.9454
24-Stunden-Volumen:
86,498
Relative Volume:
0.19
Marktkapitalisierung:
$11.45M
Einnahmen:
$41.71M
Nettoeinkommen (Verlust:
$-10.54M
KGV:
-0.8399
EPS:
-1.1757
Netto-Cashflow:
$-13.36M
1W Leistung:
+26.78%
1M Leistung:
+14.96%
6M Leistung:
-6.84%
1J Leistung:
+33.45%
1-Tages-Spanne:
$0.9454
$1.00
1-Wochen-Bereich:
$0.78
$1.00
52-Wochen-Spanne:
$0.536
$1.19
Biofrontera Inc Stock (BFRI) Company Profile
Firmenname
Biofrontera Inc
Sektor
Telefon
781-245-1325
Adresse
120 PRESIDENTIAL WAY,, WOBURN
Compare BFRI vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.983 | 11.41M | 41.71M | -10.54M | -13.36M | -1.1757 |
TAK
Takeda Pharmaceutical Co Adr
|
18.20 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.16 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.935 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.67 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
554.53 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Biofrontera Inc Aktie (BFRI) Neueste Nachrichten
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 - marketscreener.com
BFRI Technical Analysis & Stock Price Forecast - Intellectia AI
Portfolio Shifts: Is now the right time to enter Biofrontera Inc Equity WarrantGap Down & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Biofrontera (BFRI) Projected to Post Earnings on Friday - Defense World
Risk Report: How does Biofrontera Inc Equity Warrant compare to its peersWeekly Market Outlook & Real-Time Sentiment Analysis - baoquankhu1.vn
Moving Averages: Can Biofrontera Inc stock outperform in a bear marketTrade Analysis Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Biofrontera Inc PE Ratio (TTM) & PE Ratio (TTM) ChartsBFRI - GuruFocus
Biofrontera reports rise in Q4 revenue, turns profitable - MSN
If You Invested $1,000 in Biofrontera Inc (BFRI) - Stock Titan
Layoff Watch: Is Biofrontera Inc forming a breakout pattern2026 PostEarnings & High Conviction Buy Zone Alerts - baoquankhu1.vn
Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - ca.investing.com
BFRI PE Ratio & Valuation, Is BFRI Overvalued - Intellectia AI
Biofrontera’s New Royalty Agreement Drives Gross Margins Above 82%, Opening Up New Profit Opportunities - Bitget
Biofrontera Inc. (NASDAQ:BFRI) Q4 2025 Earnings Call Transcript - Insider Monkey
Biofrontera 2025 Company Overview: Ameluz Photodynamic Therapy, Product Pipeline, and U.S. Market Strategy - Minichart
Biofrontera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Biofrontera Earnings Call: Profits Rise, Risks Remain - tipranks.com
BFRIW SEC FilingsBiofrontera 10-K, 10-Q, 8-K Forms - Stock Titan
BIOFRONTERA ($BFRI) Releases Q4 2025 Earnings - quiverquant.com
[10-K] Biofrontera Inc. Files Annu... - Stock Titan
Biofrontera outlines 80%-85% gross margin target for 2026 following strategic asset acquisition - MSN
Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Biofrontera Inc. Q4 2025 sees record revenue growth - Investing.com Australia
Biofrontera 2025 Financial Results: Record Annual & Quarterly RevenueNews and Statistics - IndexBox
Biofrontera Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Biofrontera (BFRI) Q4 2025 Financial Results Transcript - Bitget
Biofrontera (BFRI) Q4 2025 Earnings Transcript - The Globe and Mail
BFRI: Record revenue, improved margins, and clinical progress set up strong 2026 growth - TradingView
Earnings call transcript: Biofrontera Inc. Q4 2025 sees record revenue growth By Investing.com - Investing.com South Africa
Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year - tipranks.com
Biofrontera reports record Q4 revenue $17.1M, Q4 gross margin 82.4% and Q4 net income $5.6M - TradingView
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - The Manila Times
Record Q4 for Biofrontera (NASDAQ: BFRI) with 36% revenue growth - Stock Titan
Price Action: Does Biofrontera Inc have a sustainable dividend2026 Pullbacks & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Nasdaq Moves: Does Biofrontera Inc Equity Warrant have pricing power2026 Snapshot & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Biofrontera Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Biofrontera Inc expected to post earnings of 20 cents a shareEarnings Preview - TradingView
BFRIWBiofrontera Latest Stock News & Market Updates - Stock Titan
Analysts Offer Insights on Healthcare Companies: OS Therapies Incorporated (OSTX), Legend Biotech (LEGN) and Biofrontera (BFRI) - The Globe and Mail
Biofrontera (BFRI) to Release Earnings on Thursday - Defense World
Are healthcare shares trailing behind Align Technology (ALGN) in performance this year? - Bitget
PTA-Adhoc: Biofrontera AG: Financial Guidance for FY 2026 - TradingView
Market Rankings: Is Biofrontera Inc backed by strong institutional buying2026 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Bitget
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - The Manila Times
Biofrontera Inc. to Report Fourth Quarter and Full Year - GlobeNewswire
Biofrontera Inc. (BFRI) upgraded to buy: Here's why - msn.com
Biofrontera reports Phase 2b acne trial results for Ameluz PDT - Investing.com India
Biofrontera Reports Positive Phase 2b Acne Trial Results - TipRanks
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - The Manila Times
Biofrontera reports positive Phase 2b Ameluz PDT results for moderate to severe acne - TradingView
Finanzdaten der Biofrontera Inc-Aktie (BFRI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):